Abstract library

13 results for "Schrader".
#2707 Investigating the Crosstalk between MEN1, p53 and Notch Reveals Biomarkers of Formation of Primary Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of endocrine tumors. Previous studies showed that mutations of p53 are extremely rare; whereas genetic changes of MEN1 frequently occur and are correlated with poor prognosis in PNET. Still, their roles in tumorigenesis remain elusive.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Ylenia Capodanno
#2827 Characterization of Epigenetic Modulation in Pancreatic Neuroendocrine Neoplasms
Introduction: Pancreatic neuroendocrine tumors (PanNETs) represent a rare and heterogeneous tumor entity. Despite advances in therapy cancer progression and resistance mechanisms are still challenging. Recent genome wide sequencing analyses in PanNETs identified a large number of mutated genes involved in epigenetic modulation.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: MD Sebastian Krug
#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board
Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Fabrice Viol
Authors: Viol F, Sipos B, Amin T, Fahl M, ...
#990 Prolonged Progression-Free Survival with Extended Cycle Streptozotozin/5-FU Chemotherapy in Patients with Metastatic Pancreatic Neuroendocrine Tumors
Introduction: The treatment of pancreatic neuroendocrine tumors with streptozotocin-based chemotherapy is well-established.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Joerg Schrader
Keywords: chemotherapy
#1183 Establishment of a New Human Pancreatic Neuroendocrine Tumour Cell Line
Introduction: The development of new therapeutic strategies for patients with pancreatic neuroendocrine tumours is impaired by the paucity of suitable pre-clinical models. Although the two available tumour cell lines BON and QGP have a neuroendocrine phenotype, the proliferation rate is too high for a well differentiated neuroendocrine tumour.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Schrader J, Benten D, Rhotert C, Fahl M, ...
#1527 Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy (PRRT) Lu-177-DOTA-TATE (Lu-177) in Patients with Advanced Neuroendocrine Tumours (NET).
Introduction: PRRT using Lu-177 is a treatment option for advanced NETs.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Alexander Mc Ewan
#1542 Selective Inhibition of PI3Kalpha (BYL719) - Promising Therapeutic Option for Neuroendocrine Tumors?
Introduction: Neuroendocrine tumors are heterogeneous, often functional malignancies and their therapeutic options are limited. As the PI3 kinase signaling is ­in GEP-NENs, selective PI3Kalpha inhibitors may be more potent than panPI3K inhibitors.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PD Dr. Patricia Grabowski
#1553 A Novel In Vitro Model of a Highly Proliferative Pancreatic Neuroendocrine Neoplasia
Introduction: Transformation of well-differentiated neuroendocrine tumors into highly proliferative neuroendocrine neoplasms is a rare, but clinical relevant phenomenon. So far, it is unclear whether these tumors should be treated in analogy to neuroendocrine tumors or as bona fide neuroendocrine carcinoma.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Behrang Y, Benten D, Erbes J, Eggers C, ...
Keywords: cell line
#1573 Regulation of Neuroendocrine Differentiation by Growth Factor Induced Proliferation in a Well-differentiated Pancreatic Neuroendocrine Tumor Cell Line
Introduction: The regulation of neuroendocrine differentiation in NET tumor cells is poorly understood. Clinical experience suggests a correlation between proliferation and neuroendocrine de-differentiation.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Behrang Y, Benten D, Fahl M, Eggers C, ...
#1867 Establishment of the First Well-Differentiated in Vivo Human Pancreatic Neuroendocrine Tumor Model
Introduction: The development of new therapeutic strategies for cancer patients relies on the in vitro and in vivo testing of novel substances in the pre-clinical setting. So far, this has not been possible for pancreatic neuroendocrine tumors (pNET) due to lack of suitable animal models resembling the disease course in human patients.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Joerg Schrader
Authors: Schrader J, Unrau L, Stahl F, Eggers C, ...
Keywords: pNET, insulinoma, SSTR